Aclarion, Inc. (ACON) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changi ...

Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a Peer-to-Peer Magazine Published by Siemens to Showcase Advancing Technologies in the MRI Space The RSNA Edition Coincides With the Annual Meeting of the Radiology Society of North America (RSNA) BROOMFIELD, Colo., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is l ...

营收情况 - 2024年第三季度营收14407美元较2023年同期减少4658美元降幅24%主要因特定临床活动结束[126] - 2024年前三季度营收35492美元较2023年同期减少26115美元降幅42%因特定临床活动结束[135] 营收成本 - 2024年第三季度营收成本21332美元较2023年同期增加9%因营收组合变化致合作伙伴费用增加[127] - 2024年前三季度营收成本64102美元较2023年同期增加14%因托管成本价格上涨和营收组合变化[136] 销售和营销费用 - 2024年第三季度销售和营销费用232775美元较2023年同期增加39879美元增幅21%[128] - 2024年前三季度销售和营销费用638869美元较2023年同期增加60900美元增幅11%[138] 研发费用 - 2024年第三季度研发费用195797美元较2023年同期减少2455美元降幅1%[129] - 2024年前三季度研发费用636940美元较2023年同期减少15717美元降幅2%[139] 一般和管理费用 - 2024年第三季度一般和管理费用860461美元较2023年同期增加89927美元增幅12%[130] 利息费用 - 2024年第三季度利息费用71527美元较2023年同期减少94805美元[131] 公司资金相关交易 - 2024年1月22 - 29日公司以644142股普通股交换1519779美元本金及应计利息产生1066732美元费用[142] - 2024年3月6日公司支付300974美元本金及应计利息产生111928美元费用[142] 公允价值调整与其他净收入 - 2024年9个月内公司记录了330632美元的公允价值有利调整[143] - 2024年9个月其他净收入为93284美元[144] 现金活动 - 2024年9个月经营活动使用现金4348748美元[159] - 2024年9个月投资活动使用现金261220美元[160] - 2024年9个月融资活动提供现金4900996美元[158] - 2024年9个月内公司完成5175000单位的公开发行每股0.58美元总收益约300万美元[155] - 截至2024年9月30日公司有现金包括10000美元受限现金共1322098美元[157] 资金筹集需求 - 公司认为需要筹集额外资金来继续技术开发[152] 财务报告内部控制 - 2023年12月31日公司财务报告内部控制无效原因包括职责分离有限缺乏正式控制文件资源少员工少缺乏足够会计资源[184] - 2023年第三季度公司聘请外部公司提供会计支持增加职责分离[185] - 截至2024年9月30日的九个月内公司与外部公司合作建立最佳实践以改进财务报告内部控制相关披露[183] - 截至2024年9月30日的九个月内公司继续与外部公司合作建立最佳实践以增强财务报告内部控制[185] - 截至2024年9月30日的季度内除上述补救措施外无影响财务报告内部控制的变更[186] 法律诉讼情况 - 公司目前未涉及管理层认为会对运营或财务状况产生重大不利影响的重大法律诉讼[188]

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion’s CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group ...

Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Com ...

文章核心观点 - 公司专注于开发非侵入性工具,帮助医生识别脊柱盘疼痛的来源,有望革新慢性腰痛的标准治疗[1] - 公司的Nociscan平台利用增强智能算法和生物标记物,在慢性疼痛治疗方面取得突破性进展[1] - 公司已获得超过50百万美元的AI平台投资,并在英国获得了Nociscan的支付者覆盖,正在向标准护理地位迈进[1] 根据目录分别总结 Nociscan在临床试验中的重要作用 - Nociscan被选中参与正在进行的挪威LIFEHAB临床试验,该试验旨在评估Nociscan的磁共振波谱(MRS)生物标记物在确定最佳治疗方案方面的作用[2] - 公司正在等待罗马完成的一项试验以及两项美国国立卫生研究院资助的研究的结果,这些研究都在探讨Nociscan在治疗腰痛中的作用[2] - 公司的CLARITY试验将在8个试验点招募多达300名患者,旨在验证Nociscan提高手术结果的能力[2] 临床采用和研究的扩展 - 公司正在与10名全球顶尖脊柊外科医生合作,他们认识到公司技术的临床价值,这有助于推动支付者的覆盖决策[3] - 公司正在美国关键市场拓展合作伙伴关系,瞄准人身伤害和工伤赔付领域,利用其经过验证的Nociscan技术[3]

Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial in Norway Comparing Lumbar Interbody Fusion Surgery With Multidisciplinary Rehabilitation LIFEHAB Joins the NIH and Rome in Selecting Nociscan as a Technology to Help Determine Which Discs to Treat and the Technology’s Role in Selecting Optimal Treatment Options BROOMFIELD, CO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ...

Aclarion Added to PRISM Emerging Medical Devices Index Company’s industry-first technology addresses chronic low back painAclarion secured its first commercial agreement with Michigan’s Sheridan Community HospitalPRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtechNEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to th ...

Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population Average Settlement in New Jersey for Personal Injury Claims Involving the Neck and Back is $918,967 Work-related Accidents Which Cause Neck and Back Injuries Have a National Average Settlement of $148,750 BROOMFIELD, CO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACON ...

CLUE is a Multi-center Trial to Identify how Often Nociscan’s AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chr ...